

REGENERON PHARMACEUTICALS INC

Form 8-K

January 09, 2009

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 9, 2009**

**REGENERON PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**New York**

**000-19034**

**13-3444607**

(State or other jurisdiction of  
incorporation)

(Commission File Number)

(I.R.S. Employer  
Identification Number)

**777 Old Saw Mill River Road, Tarrytown, New  
York**

**10591-6707**

(Address of principal executive offices)

(Zip Code)

**(914) 347-7000**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 7.01 Regulation FD Disclosure

Item 9.01 Financial Statements and Exhibits

Exhibit Index

EX-99.A: SLIDES

---

**Table of Contents**

**Item 7.01 Regulation FD Disclosure**

Attached as Exhibit 99(a) are slides that Regeneron Pharmaceuticals, Inc. intends to use in conjunction with meetings with investors at the J.P. Morgan 27<sup>th</sup> Annual Healthcare Conference in San Francisco on January 12-15, 2009.

**Item 9.01 Financial Statements and Exhibits**

(c) Exhibits

99(a) Slides that Regeneron Pharmaceuticals, Inc. intends to use in conjunction with meetings with investors at the J.P. Morgan 27<sup>th</sup> Annual Healthcare Conference in San Francisco on January 12-15, 2009.

**Table of Contents**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REGENERON PHARMACEUTICALS,  
INC.

Dated: January 9, 2009

By: /s/ Stuart Kolinski  
Stuart Kolinski  
Senior Vice President and General  
Counsel

3

---

**Table of Contents**

**Exhibit Index**

**Number Description**

99(a) Slides that Regeneron Pharmaceuticals, Inc. intends to use in conjunction with meetings with investors at the J.P. Morgan 27<sup>th</sup> Annual Healthcare Conference in San Francisco on January 12-15, 2009.

4